vedotin-话题@MedSci - 梅斯（MedSci）

#vedotin#

36篇内容 | 1696人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1527035, encodeId=71c1152e035e0, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Brentuximab vedotin联合用药有效改善复发/难治霍奇金淋巴瘤预后, objectType=article, longId=168147, objectId=52db16814e29, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52db16814e29, replyNumber=0, likeNumber=66, createdTime=2019-06-13, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52db16814e29, moduleTitle=Brentuximab vedotin联合用药有效改善复发/难治霍奇金淋巴瘤预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=52db16814e29)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527034, encodeId=6248152e03416, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=brentuximab vedotin治疗淋巴瘤优势显著，不受CD30表达限制, objectType=article, longId=167948, objectId=c2f816e9487a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2f816e9487a, replyNumber=0, likeNumber=67, createdTime=2019-06-11, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2f816e9487a, moduleTitle=brentuximab vedotin治疗淋巴瘤优势显著，不受CD30表达限制, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c2f816e9487a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527033, encodeId=df65152e03374, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=ASCO 2019：Brentuximab vedotin治疗淋巴瘤优势显著，不依赖CD30表达, objectType=article, longId=167885, objectId=c23216e88573, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c23216e88573, replyNumber=0, likeNumber=69, createdTime=2019-06-10, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c23216e88573, moduleTitle=ASCO 2019：Brentuximab vedotin治疗淋巴瘤优势显著，不依赖CD30表达, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c23216e88573)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527032, encodeId=ab2f152e03267, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Lancet oncol：Polatuzumab vedotin联合免疫化疗用于弥漫性大B细胞淋巴瘤的安全性和疗效, objectType=article, longId=166508, objectId=9b0116650850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b0116650850, replyNumber=0, likeNumber=58, createdTime=2019-05-22, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b0116650850, moduleTitle=Lancet oncol：Polatuzumab vedotin联合免疫化疗用于弥漫性大B细胞淋巴瘤的安全性和疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9b0116650850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527031, encodeId=6ad5152e03139, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Lancet haemat： Polatuzumab vedotin或Pinatuzumab vedotin联合利妥昔单抗用于复发性/难治性非霍奇金淋巴瘤的疗效, objectType=article, longId=164439, objectId=effa16443993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=effa16443993, replyNumber=0, likeNumber=52, createdTime=2019-04-18, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=effa16443993, moduleTitle=Lancet haemat： Polatuzumab vedotin或Pinatuzumab vedotin联合利妥昔单抗用于复发性/难治性非霍奇金淋巴瘤的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=effa16443993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527030, encodeId=daf4152e030d2, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Lancet oncol：Tisotumab vedotin可安全治疗多种固体肿瘤, objectType=article, longId=159649, objectId=7e3e15964939, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e3e15964939, replyNumber=0, likeNumber=78, createdTime=2019-02-10, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e3e15964939, moduleTitle=Lancet oncol：Tisotumab vedotin可安全治疗多种固体肿瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7e3e15964939)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527029, encodeId=7d6a152e0292c, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Blood：Brentuximab Vedotin+CHP一线治疗外周T细胞淋巴瘤5年结局喜人：客观反应率高达100%！, objectType=article, longId=138647, objectId=e39113864ec6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e39113864ec6, replyNumber=0, likeNumber=36, createdTime=2018-05-21, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e39113864ec6, moduleTitle=Blood：Brentuximab Vedotin+CHP一线治疗外周T细胞淋巴瘤5年结局喜人：客观反应率高达100%！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e39113864ec6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527028, encodeId=ddc9152e02846, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Blood：Brentuximab vedotin联合苯达莫司汀作为一线补救疗法用于复发性/难治性HL的疗效和安全性, objectType=article, longId=137013, objectId=ee2913e013e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee2913e013e6, replyNumber=0, likeNumber=96, createdTime=2018-05-04, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee2913e013e6, moduleTitle=Blood：Brentuximab vedotin联合苯达莫司汀作为一线补救疗法用于复发性/难治性HL的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ee2913e013e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527027, encodeId=8c60152e027d3, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性, objectType=article, longId=131784, objectId=6781131e84a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6781131e84a3, replyNumber=0, likeNumber=40, createdTime=2018-03-09, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6781131e84a3, moduleTitle=Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6781131e84a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527026, encodeId=74e9152e0269d, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=姜文奇教授：Brentuximab Vedotin联合AVD一线治疗中晚期霍奇金淋巴瘤可显著改善无复发生存, objectType=article, longId=123411, objectId=11981234112e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11981234112e, replyNumber=0, likeNumber=101, createdTime=2017-12-16, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11981234112e, moduleTitle=姜文奇教授：Brentuximab Vedotin联合AVD一线治疗中晚期霍奇金淋巴瘤可显著改善无复发生存, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=11981234112e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527025, encodeId=09d9152e025f6, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Blood：Brentuximab vedotin联合nivolumab用于治疗霍奇金淋巴瘤的效果。, objectType=article, longId=123243, objectId=fe1312324341, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe1312324341, replyNumber=0, likeNumber=76, createdTime=2017-12-14, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe1312324341, moduleTitle=Blood：Brentuximab vedotin联合nivolumab用于治疗霍奇金淋巴瘤的效果。, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fe1312324341)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527024, encodeId=cad3152e024f3, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案, objectType=article, longId=123207, objectId=4dfc12320e42, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dfc12320e42, replyNumber=0, likeNumber=70, createdTime=2017-12-14, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dfc12320e42, moduleTitle=【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4dfc12320e42)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527023, encodeId=a42c152e02301, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Blood：brentuximab vedotin联合达卡巴嗪或苯达莫司汀用于HL老年患者的安全性和治疗效果。, objectType=article, longId=116500, objectId=e5fb11650085, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5fb11650085, replyNumber=0, likeNumber=80, createdTime=2017-10-19, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5fb11650085, moduleTitle=Blood：brentuximab vedotin联合达卡巴嗪或苯达莫司汀用于HL老年患者的安全性和治疗效果。, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e5fb11650085)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527022, encodeId=e81d152e02261, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Blood：brentuximab vedotin治疗复发或难治性系统性间变性大细胞淋巴瘤的2期临床报告, objectType=article, longId=115405, objectId=751111540543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=751111540543, replyNumber=0, likeNumber=60, createdTime=2017-10-09, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=751111540543, moduleTitle=Blood：brentuximab vedotin治疗复发或难治性系统性间变性大细胞淋巴瘤的2期临床报告, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=751111540543)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527021, encodeId=23ae152e021b3, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Haematologica：Brentuximab vedotin治疗复发/难治性系统性间变性大细胞淋巴瘤的大型观察性研究（意大利真实世界研究）, objectType=article, longId=107875, objectId=aa2c10e8756a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa2c10e8756a, replyNumber=0, likeNumber=46, createdTime=2017-08-07, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa2c10e8756a, moduleTitle=Haematologica：Brentuximab vedotin治疗复发/难治性系统性间变性大细胞淋巴瘤的大型观察性研究（意大利真实世界研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=aa2c10e8756a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527020, encodeId=4772152e02009, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Lancet：Brentuximab vedotin治疗霍奇金淋巴瘤的研究, objectType=article, longId=48877, objectId=c20f488e7cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c20f488e7cd, replyNumber=0, likeNumber=64, createdTime=2015-04-03, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c20f488e7cd, moduleTitle=Lancet：Brentuximab vedotin治疗霍奇金淋巴瘤的研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c20f488e7cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

vedotin

2020-05-29

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Brentuximab vedotin联合用药有效改善复发/难治霍奇金淋巴瘤预后

2019-06-13

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

brentuximab vedotin治疗淋巴瘤优势显著，不受CD30表达限制

2019-06-11

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

ASCO 2019：Brentuximab vedotin治疗淋巴瘤优势显著，不依赖CD30表达

2019-06-10

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Lancet oncol：Polatuzumab vedotin联合免疫化疗用于弥漫性大B细胞淋巴瘤的安全性和疗效

2019-05-22

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Lancet haemat： Polatuzumab vedotin或Pinatuzumab vedotin联合利妥昔单抗用于复发性/难治性非霍奇金淋巴瘤的疗效

2019-04-18

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Lancet oncol：Tisotumab vedotin可安全治疗多种固体肿瘤

2019-02-10

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Blood：Brentuximab Vedotin+CHP一线治疗外周T细胞淋巴瘤5年结局喜人：客观反应率高达100%！

2018-05-21

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Blood：Brentuximab vedotin联合苯达莫司汀作为一线补救疗法用于复发性/难治性HL的疗效和安全性

2018-05-04

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性

2018-03-09

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

姜文奇教授：Brentuximab Vedotin联合AVD一线治疗中晚期霍奇金淋巴瘤可显著改善无复发生存

2017-12-16

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Blood：Brentuximab vedotin联合nivolumab用于治疗霍奇金淋巴瘤的效果。

2017-12-14

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案

2017-12-14

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Blood：brentuximab vedotin联合达卡巴嗪或苯达莫司汀用于HL老年患者的安全性和治疗效果。

2017-10-19

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Blood：brentuximab vedotin治疗复发或难治性系统性间变性大细胞淋巴瘤的2期临床报告

2017-10-09

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Haematologica：Brentuximab vedotin治疗复发/难治性系统性间变性大细胞淋巴瘤的大型观察性研究（意大利真实世界研究）

2017-08-07

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Lancet：Brentuximab vedotin治疗霍奇金淋巴瘤的研究

2015-04-03

科室
- - 订阅+
  - 更多科室
工具
服务